Navigation Links
Intercell AG Appoints Staph Leavenworth Bakali as Chief Business Officer
Date:9/30/2010

VIENNA, Sept. 30 /PRNewswire/ -- Intercell AG (VSE: ICLL) today announced that effective October 1, 2010, Staph Leavenworth Bakali will join its Management Board as Chief Business Officer with key responsibilities for the commercial aspects of the Company, directly leading Marketing and Sales, Corporate and Business Development, and Alliance Management. Staph will also play a key role with the other Management Board members in helping drive forward the Company's strategy. Prior to the appointment to Intercell AG's Management Board, Staph had stepped down from his position as member of the Supervisory Board of the company.

"Staph has an outstanding track record in the vaccines industry and has made major contributions to the success of some key vaccines businesses globally. His commercial and strategic experience ideally complement the skills of our current Management Board," said Gerd Zettlmeissl, Chief Executive Officer of Intercell AG. "We are proud to have Staph working with us towards the next growth phase of our Company."

"Having been a member of Intercell's Supervisory Board for almost five years, I have been impressed with the progress and capabilities of the Company and its people in creating value through innovation, industrialization and commercialization," said Staph Bakali. "I am delighted to join a very dynamic team and look forward to helping develop the business further."

Staph brings 20 years of vaccine industry experience from his previous leadership positions. He was recently Chief Executive Officer of Genocea Biosciences, a Boston (U.S.) based innovative biotech vaccine company, and previously Chief Operating Officer for ID Biomedical (Vancouver, Canada) and PowderJect (Oxford, UK), which were acquired by GlaxoSmithKline and Chiron, respectively. Staph Bakali was also previously head of Sales and Marketing for Chiron's global vaccine business and SmithKline Beecham's Vaccine Business Unit in France. Staph holds a Masters degree in Management from the London Business School.

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.


'/>"/>
SOURCE Intercell AG
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Intercell Acquires Antibody Technology Platform to Further Exploit Its Capabilities to Combat Infectious Diseases
2. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
3. Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine
4. Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers Diarrhea Vaccine Study
5. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
6. Favourable Six Months Follow-Up Results From Intercells Phase II Therapeutic Hepatitis C Program
7. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
8. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
9. 3-V Biosciences Appoints Merdad V. Parsey, MD, PhD, as Chief Executive Officer
10. Tigris Pharmaceuticals Appoints Neil Flanzraich to Executive Chairman of the Board
11. Laureate Pharma Appoints Steven R. Johnson as Vice President, Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... Services, Inc. (NYSE: WST ) today announced ... financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record high, ... constant currency (organic) grew by 3.9%. ... in the prior-year quarter. Second-quarter 2017 adjusted diluted EPS ...
(Date:7/26/2017)... July 27, 2017  Radium Medical Aesthetics, a leading medical aesthetic ... delay aging by effectively addressing several skin conditions from the inside. ... become rougher and more fragile. The skin becomes more transparent due ... to the harmful UV rays from the sun contributes to aging ... ...
(Date:7/26/2017)... 26, 2017 The Galien Foundation announced ... USA Award Nominees. Counted among the global ... recognizes outstanding biomedical and technology product achievement that improves the ... qualify, each candidate must be U.S. Food and Drug Administration ... demonstrate tremendous potential to impact human health. Sales data are ...
Breaking Medicine Technology:
(Date:8/15/2017)... ... 2017 , ... The Philadelphia Marathon and the American Association for Cancer Research ... the City’s commitment to improving the health of its citizens. Dedicated to preventing and ... healthy lifestyle as research shows this can help reduce the risk of cancer. ...
(Date:8/15/2017)... ... August 15, 2017 , ... ... proud to announce the 19th Annual V Foundation Wine Celebration raised nearly $9 ... included more than $7 million in “Fund-A-Need” donations to support the study of ...
(Date:8/15/2017)... (PRWEB) , ... August 15, 2017 , ... ... provide supplemental information about a patient’s periodontal disease . This information can ... help establish the therapy endpoint. , The two salivary diagnostic tests, named MyPerioPath® ...
(Date:8/15/2017)... ... August 15, 2017 , ... ... Applicator, which makes treating smaller, hard-to-reach areas of the body like the arms ... AVIE! MedSpa also utilizes CoolAdvantage™ technology for their CoolSculpting treatments, which cuts treatment ...
(Date:8/15/2017)... ... August 15, 2017 , ... Meals ... Pack initiative providing thousands of Medicare-eligible seniors with five days of nutritious and ... during the 2017 hurricane season. , “Being prepared for catastrophic weather ...
Breaking Medicine News(10 mins):